Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
QuintilesIMS
US Department of Justice
Daiichi Sankyo
McKesson
Farmers Insurance
Harvard Business School
Mallinckrodt
Medtronic
Julphar

Generated: January 19, 2018

DrugPatentWatch Database Preview

SKELAXIN Drug Profile

« Back to Dashboard

When do Skelaxin patents expire, and what generic alternatives are available?

Skelaxin is a drug marketed by King Pharms and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in SKELAXIN is metaxalone. There are twenty drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the metaxalone profile page.
Summary for SKELAXIN
Drug patent expirations by year for SKELAXIN
Pharmacology for SKELAXIN

US Patents and Regulatory Information for SKELAXIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-003 Aug 30, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-003 Aug 30, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SKELAXIN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 800 mg ➤ Subscribe 11/4/2004

Non-Orange Book US Patents for SKELAXIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,378,434 Metaxalone products, method of manufacture, and method of use ➤ Subscribe
8,168,664 Metaxalone products, method of manufacture, and method of use ➤ Subscribe
6,683,102 Methods of using metaxalone in the treatment of musculoskeletal conditions ➤ Subscribe
6,407,128 Method for increasing the bioavailability of metaxalone ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Deloitte
AstraZeneca
McKinsey
Daiichi Sankyo
Colorcon
Fuji
Chinese Patent Office
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot